MPM BioImpact Innovations Equities Master, LP
MPM BioImpact Innovations Equities Master, LP is a hedge fund based in Boston, Massachusetts. According to its most recent Form D, filed Jun 26, 2026, the fund has sold $105,210,597 of interests to 10 investors since its first sale in Jun 2024. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Christiana Bardon; MPM BioImpact Innovations Equities GP, LLC; Kristen Laguerre.
Performance
No verified returns have been reported for this fund. As a rough guide, MPM Bioimpact, which manages it, disclosed U.S. stock holdings that returned an estimated +50.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based only on its public 13F filings. Over a longer period, Q3 2024 to Q2 2026, the estimate is +91.0% (S&P 500: +37.2%).
This estimate covers the firm's whole disclosed long U.S. stock portfolio. It is not this fund's return and excludes dividends, fees, shorts, derivatives, bonds, cash and trading within each quarter.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $105,210,597Cumulative sales reported on Form D
- Investors
- 10
- First sale
- Jun 3, 2024
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Christiana Bardon; MPM BioImpact Innovations Equities GP, LLC; Kristen Laguerre
- Latest Form D
- Jun 26, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about MPM BioImpact Innovations Equities Master, LP
What is the minimum investment for MPM BioImpact Innovations Equities Master, LP?
MPM BioImpact Innovations Equities Master, LP's latest Form D, filed Jun 26, 2026, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in MPM BioImpact Innovations Equities Master, LP?
MPM BioImpact Innovations Equities Master, LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has MPM BioImpact Innovations Equities Master, LP raised?
MPM BioImpact Innovations Equities Master, LP reports $105,210,597 sold from 10 investors on its Form D filed Jun 26, 2026. This is cumulative sales since the offering began, not current assets or performance.
Where is MPM BioImpact Innovations Equities Master, LP based?
MPM BioImpact Innovations Equities Master, LP is based in Boston, Massachusetts and is managed by MPM Bioimpact.
When did MPM BioImpact Innovations Equities Master, LP launch?
MPM BioImpact Innovations Equities Master, LP reports its first sale in Jun 2024.
Size compared with every hedge fund
Raised more than 49% of the 474 hedge funds based in Massachusetts, and more than 59% of all 10,308 that report sales.